乳腺癌和前列腺癌骨转移中99mTc-HDP SPECT/CT与18F-NaF PET/CT的标准化摄取值比较
结果显示两种方法SUV强相关(R²≥0.80,p<0.001),但PET SUV显著更高;SUVR差异较小,提示SPECT可用于骨代谢的临床定量。
要点
- 99mTc-HDP SPECT/CT与18F-NaF PET/CT的SUV在骨病灶中强相关(R²≥0.80,p<0.001)。
- PET的SUVmax、SUVpeak、SUVmean均显著高于SPECT(p<0.001),中位差异分别为21%、12%、19%。
- SPECT与PET的SUVR差异较小,中位差异分别为2%、-9%、2%。
核心结论
- 99mTc-HDP SPECT/CT与18F-NaF PET/CT的SUV强相关且SUVR相似,表明SPECT可用于乳腺癌和前列腺癌骨转移骨代谢的临床定量。
研究设计与样本
- SPECT和PET数据采用有序子集期望最大化算法重建获得定量图像。
- 分析两种图像均可见的转移性和良性骨病灶,测定SUVmax、SUVpeak、SUVmean及病灶与邻近正常骨的SUVR。
主要发现
- 共分析231个骨病灶,其中129个转移性、102个良性。
- 所有病灶纳入分析时,SPECT与PET的三种SUV均强相关(R²≥0.80,p<0.001)。
- PET的SUV显著高于SPECT(p<0.001),SUVmax、SUVpeak、SUVmean的中位差异分别为21%、12%、19%。
- SPECT与PET的SUVR相似,SUVRmax、SUVRpeak、SUVRmean的中位差异分别为2%、-9%、2%。
关键数值与推荐
- SUV强相关定义为R²≥0.80且p<0.001。
- PET与SPECT的SUV中位差异:SUVmax 21%、SUVpeak 12%、SUVmean 19%。
- PET与SPECT的SUVR中位差异:SUVRmax 2%、SUVRpeak -9%、SUVRmean 2%。
临床怎么用
- 在乳腺癌和前列腺癌骨转移患者中,可采用99mTc-HDP SPECT/CT进行骨代谢的定量评估。
- 解读SPECT SUV时需注意其绝对值低于PET SUV,但SUVR与PET接近,更适合用于病灶与正常骨的相对比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite recent technological advances allowing for quantitative single-photon emission computed tomography (SPECT), quantitative SPECT has not been widely used in the clinical practice. The aim of this study is to evaluate the feasibility of quantitative SPECT for measuring metastatic bone uptake in breast and prostate cancer by comparing standard uptake values (SUVs) measured with 99mTc-HDP SPECT/CT and 18F-NaF PET/CT. METHODS: Twenty-six breast and 27 prostate cancer patients at high risk of bone metastases underwent both 99mTc-HDP SPECT/CT and 18F-NaF PET/CT within 14 days of each other. The SPECT and PET data were reconstructed using ordered-subset expectation-maximization algorithms achieving quantitative images. Metastatic and benign skeletal lesions visible in both data sets were identified, and their maximum, peak, and mean SUVs (SUVmax, SUVpeak, and SUVmean) were determined. SUV ratios (SUVRs) between the lesions and adjacent normal appearing bone were also calculated. Linear regression was used to evaluate the correlations between the SUVs of SPECT and PET and Bland-Altman plots to evaluate the differences between the SUVs and SUVRs of SPECT and PET. RESULTS: A total of 231 skeletal lesions, 129 metastatic and 102 benign, were analyzed. All three SUV measures correlated very strongly between SPECT and PET (R2 ≥ 0.80, p < 0.001) when all lesions were included, and the PET SUVs were significantly higher than SPECT SUVs (p < 0.001). The median differences were 21%, 12%, and 19% for SUVmax, SUVpeak, and SUVmean, respectively. On the other hand, the SUVRs were similar between SPECT and PET with median differences of 2%, - 9%, and 2% for SUVRmax, SUVRpeak, and SUVRmean, respectively. CONCLUSION: The strong correlation between SUVs and similar SUVRs of 99mTc-HDP SPECT/CT and 18F-NaF PET/CT demonstrate that SPECT is an applicable tool for clinical quantification of bone metabolism in osseous metastases in breast and prostate cancer patients.
引用
- Arvola S, Jambor I, Kuisma A, et al. Comparison of standardized uptake values between 99mTc-HDP SPECT/CT and 18F-NaF PET/CT in bone metastases of breast and prostate cancer. EJNMMI Res. 2019. PMID: 30680469. doi:10.1186/s13550-019-0475-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。